HeartBeam, Inc. is a medical technology company that specializes in cardiac monitoring solutions. The company is traded as BEAT on the stock exchange, highlighting the centrality of its heart monitoring mission. Founded in 2012, HeartBeam, Inc. differs from conventional cardiac monitoring companies with their innovative approach to patient care, focusing primarily on offering real-time heart monitoring to patients, regardless of their location.
The company's central product is a proprietary, FDA-approved ECG-monitoring device capable of providing real-time heart rate and EKG data. It's a transformative solution for the cardiology field, enabling doctors to monitor their patients' heart health 24/7 remotely. This means patients do not have to be in a hospital or doctor's office to have their heart health continuously monitored. Instead, the HeartBeam device allows patients to continue with their regular life routines, without compromising on the quality of their healthcare.
Moreover, the device is user-friendly, making it comfortable for patients to wear and easy to operate, while the data it provides is accurate, consistent, and reliable. It can detect any irregularities in heartbeat patterns, prompting quick action and potentially saving lives even before apparent symptoms manifest.
However, the main strength of HeartBeam, Inc. lies in the integration of its device with advanced telemedicine practices. This synergistic approach offers a robust line of defense against cardiac conditions, dramatically reducing the time between the onset of symptoms and the delivery of necessary medical intervention. With the support of its technology, HeartBeam facilitates real-time communication between patients and medical professionals, ensuring immediate response to changes in patients’ cardiac behavior.
Despite being a relatively young company, HeartBeam has shown a positive trajectory in the health tech industry. Their commitment to improving patient care through innovative, remote monitoring solutions has garnered them a rapidly growing number of users, which in turn has stimulated significant stock market interest in BEAT.
All in all, HeartBeam Inc. represents the cutting-edge intersection of medical technology, patient care, and telecommunication. By reshaping how cardiac care is managed and delivered, HeartBeam could be a game-changer, not only in the heart health sector but in the broader scope of patient-centered healthcare solutions. As the company moves forward, it is expected to continue pushing the boundaries and setting new benchmarks for integrated healthcare systems.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

HeartBeam Inc. has secured a new U.S. patent that integrates acoustic sensing and thoracic impedance measurement into its existing ECG device platform. This advancement allows the device to function as a "digital stethoscope" for assessing heart valve function and fluid accumulation, crucial for earlier detection of structural heart issues and heart failure. The patent strengthens HeartBeam's intellectual property and strategy for a multi-modal ambulatory cardiac sensing platform.
HeartBeam Inc. (NASDAQ: BEAT) reported a 7% decrease in operating cash outflow for Q2 2026, focusing on cost management and efficiency. The company submitted a pre-submission to the FDA for heart attack detection, with clinical trials expected by year-end, and is gaining momentum with its initial commercial launch, receiving positive feedback from physicians and patients. HeartBeam's technology, protected by 25 issued patents, includes a card, patch, and remote unit, targeting various healthcare settings and aiming to revolutionize cardiac care.
HeartBeam, Inc. (NASDAQ: BEAT) will host a conference call on Thursday, August 13, 2026, at 4:30 p.m. Eastern time to discuss its second-quarter 2026 financial results and provide updates on its strategy for global adoption of its ambulatory ECG signal platform. The call will feature Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and CFO Timothy Cruickshank, followed by a Q&A session. A presentation will accompany the webcast, and a replay will be available until August 27, 2026.